Destiny Pharma PLC - clinical stage biotechnology company based in Brighton, England - Announces appointment of Mark Wilcox to its scientific advisory board. Consultant microbiologist Wilcox is head of research and development in microbiology at the Leeds Teaching Hospitals and is lead on clostridium difficile infection for Public Health England. He also has advisory roles to UK Scientific Advisory Group for Emergencies (Covid-19), NHS England's infection prevention & control national team and Public Health England's rapid review panel.
"His knowledge compliments the existing expertise on our scientific advisory board as we plan for phase three trials for our recently acquired asset, NTCD-M3, which is targeting the prevention of clostridium difficile infection recurrence. Wilcox also brings an expert understanding of MRSA and Covid-19 hospital infections, which is valuable insight for Destiny Pharma's other preventative products in development, namely XF-73 and SPOR-COV," says Chief Scientific Officer Bill Love.
Current stock price: 114.00 pence
Year-to-date change: up 66%
By Zoe Wickens; zoewicken@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)